4.6 Article

Molecular Engineering of Exocytic Vesicle Traffic Enhances the Productivity of Chinese Hamster Ovary Cells

期刊

BIOTECHNOLOGY AND BIOENGINEERING
卷 102, 期 4, 页码 1170-1181

出版社

WILEY
DOI: 10.1002/bit.22141

关键词

secretion engineering; vesicle trafficking; exocytosis; Sec1/Munc18 proteins; therapeutic protein production; Chinese hamster ovary cells

向作者/读者索取更多资源

A complex vesicle trafficking system manages the precise and regulated distribution of proteins, membranes and other molecular cargo between cellular compartments as well as the secretion of (heterologous) proteins in mammalian cells. Sec1/Munc18 (SM) proteins are key components of the system by regulating membrane fusion. However, it is not clear how SM proteins contribute to the overall exocytosis. Here, functional analysis of the SM protein Sly1 and Munc18c suggested a united, positive impact upon SNARE-based fusion of ER-to-Golgi- and Golgi-to-plasma membrane-addressed exocytic vesicles and increased the secretory capacity of different therapeutic proteins in Chinese hamster ovary cells up to 40 pg/cell/day. Sly1- and Munc18c-based vesicle traffic engineering cooperated with Xbp-1-mediated ER/Golgi organelle engineering. Our study supports a model for united function of SM proteins in stimulating vesicle trafficking machinery and provides a generic secretion engineering strategy to improve biopharmaceutical manufacturing of important protein therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma

Haitang Yang, Sean R. R. Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A. Schmid, Swee T. Tan, Ren-Wang Peng, Feng Yao

Summary: The study revealed that loss-of-function in the upstream regulator NF2 of the Hippo pathway is associated with aberrant activation of Hippo-YAP-independent signaling, defining distinct MPM subsets with different molecular features and prognosis. This has important clinical implications for precision oncology in MPM patients.

CANCERS (2021)

Article Oncology

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

Tuo Zhang, Beibei Sun, Chenxi Zhong, Ke Xu, Zhexin Wang, Paul Hofman, Tatsuya Nagano, Antoine Legras, Biagio Ricciuti, Daniel Breadner, Duilio Divisi, Ralph A. Schmid, Ren-Wang Peng, Haitang Yang, Feng Yao

Summary: Ferroptosis inducers show high sensitivity in EGFR mutant lung cancer cells with resistance, while the histone deacetylase inhibitor Vorinostat can enhance the efficacy of ferroptosis inducers.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Article Medicine, Research & Experimental

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer

Zhang Yang, Shun-Qing Liang, Maria Saliakoura, Haitang Yang, Eric Vassella, Georgia Konstantinidou, Mario Tschan, Balazs Hegedus, Liang Zhao, Yanyun Gao, Duo Xu, Haibin Deng, Thomas M. Marti, Gregor J. Kocher, Wenxiang Wang, Ralph A. Schmid, Ren-Wang Peng

Summary: By combining FGFR1 and PLK1 inhibitors, synergistic cytotoxicity can be achieved in KRAS-mutant tumors, inducing cell death. This treatment induces apoptosis by upregulating ROS and activating the JNK/p38 pathway, while enhancing sensitivity of tumor cells to inhibitors by inhibiting autophagy.

EMBO MOLECULAR MEDICINE (2021)

Article Biochemistry & Molecular Biology

Epithelial-to-mesenchymal transition contributes to the downregulation of progesterone receptor expression in endometriosis lesions

Lijuan Ma, Thomas Andrieu, Brett McKinnon, Lea Duempelmann, Ren-Wang Peng, Carlos Wotzkow, Christoph Mueller, Michael D. Mueller

Summary: This study found a negative correlation between low expression of progesterone receptors (PR) and epithelial-to-mesenchymal transition (EMT) in endometriosis lesions. In both in vitro and in vivo experiments, EMT leads to downregulation of PR gene expression by upregulating EMT transcription factors like SNAI1 and SNAI2, potentially resulting in progesterone resistance.

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2021)

Article Oncology

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer

Zhang Yang, Shun-Qing Liang, Liang Zhao, Haitang Yang, Thomas M. Marti, Balazs Hegedus, Yanyun Gao, Bin Zheng, Chun Chen, Wenxiang Wang, Patrick Dorn, Gregor J. Kocher, Ralph A. Schmid, Ren-Wang Peng

Summary: This study reveals the metabolic dependency induced by mutant KRAS and identifies nucleolar protein 5A (NOP56) and mTOR as potential targets for the treatment of KRAS-mutant cancers. The depletion of NOP56 leads to synthetic lethal susceptibility to mTOR inhibition due to the regulation of ROS homeostasis. Co-targeting NOP56 and mTOR significantly enhances cell death in KRAS-mutant tumor cells.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma

Haitang Yang, Sabina Berezowska, Patrick Dorn, Philipp Zens, Peiru Chen, Ren-Wang Peng, Thomas M. Marti, Gregor J. Kocher, Ralph A. Schmid, Sean R. R. Hall

Summary: This study investigates the relationship between the tumor microenvironment (TME) and tumor-infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM). The results suggest that targeting the TME can potentially redirect the fate of TILs and restore anti-tumor immunity in MPM.

THERANOSTICS (2022)

Review Oncology

A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished

Wenjuan Ning, Zhang Yang, Gregor J. Kocher, Patrick Dorn, Ren-Wang Peng

Summary: KRAS is the most common oncogene in human cancers, with G12C inhibitors providing a breakthrough by covalently targeting the G12C substitution and demonstrating potent clinical efficacy. However, challenges such as drug resistance must be addressed to maximize the efficacy of KRAS(G12C) inhibitor therapy. Combination treatments with other therapeutic agents and an understanding of compensatory signaling pathways are promising strategies to overcome these challenges.

CANCERS (2022)

Review Oncology

Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?

Yanyun Gao, Marianna Kruithof-de Julio, Ren-Wang Peng, Patrick Dorn

Summary: Malignant pleural mesothelioma is a deadly cancer with limited treatment options and low survival rates. Patient-derived organoid cultures offer a promising approach for studying the disease, identifying new therapeutic targets, and developing personalized treatments.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma

Darya Karatkevich, Haibin Deng, Yanyun Gao, Emilio Flint, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti

Summary: This study found that prolonged pretreatment with pemetrexed significantly reduces cell growth in malignant pleural mesothelioma (MPM), induces cell cycle arrest, persistent DNA damage accumulation, and a senescence phenotype. Optimizing the treatment schedule by pretreatment with pemetrexed enhances the efficacy of pemetrexed-cisplatin combination therapy and may improve patient outcomes in MPM.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses

Duo Xu, Shengchen Liu, Xi Wu, Thomas M. Marti, Patrick Dorn, Ralph A. Schmid, Ren-Wang Peng, Yongqian Shu

Summary: This study investigates the immunological role of NSD3 in driving lung squamous cell carcinoma (LUSC) and provides therapeutic rationales for NSD3-amplified squamous lung cancer. The findings reveal that NSD3 amplification is associated with a non-inflamed tumor immune microenvironment (TIME) and a worse immunotherapy outcome. The high activity of unfolded protein response (UPR) signaling is identified as a key mediator for the non-immunogenic phenotype of NSD3-amplified LUSC.

CANCERS (2022)

Article Oncology

An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1

Haibin Deng, Huixiang Ge, Christelle Dubey, Tereza Losmanova, Michaela Medova, Georgia Konstantinidou, Seyran Mathilde Mutlu, Fabienne Esther Birrer, Tess Melinda Brodie, Deborah Stroka, Wenxiang Wang, Ren-Wang Peng, Patrick Dorn, Thomas Michael Marti

Summary: In this study, we modified the protocol to handle the Cre-induced KP mouse model under BSL-1 conditions by using a commercially available gutless, adeno-associated, Cre-expressing vector instead of a virus-based delivery system. The anesthesia and instillation protocols were optimized, resulting in increased productivity and reduced complications. Longitudinal monitoring of tumor growth was achieved by repeated micro-CT analysis of individual animals, significantly reducing the number of animals required per experiment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Oncology

Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients

Haitang Yang, Wenyan Ma, Beibei Sun, Liwen Fan, Ke Xu, Sean R. R. Hall, Mohammad Faisal Al-Hurani, Ralph A. Schmid, Ren-Wang Peng, Toyoaki Hida, Zhexin Wang, Feng Yao

Summary: The study found that smoking signature is a better predictor of pathological response to immunotherapy compared to PD-L1 expression, possibly due to increased TMB and/or MSI related to smoking exposure. In contrast, CT scan has poor performance in evaluating the response to immunotherapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Meeting Abstract Oncology

Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma

R. Peng, R. A. Schmid

JOURNAL OF THORACIC ONCOLOGY (2021)

Meeting Abstract Oncology

A Kinome CRISPR Screen in FGFR-Amplified Lung Cancer

Z. Yang, S. Liang, R. Peng, R. A. Schmid

JOURNAL OF THORACIC ONCOLOGY (2021)

Meeting Abstract Oncology

Investigation of Metabolic Vulnerabilities Specific to STK11-mutant Lung Cancer

Y. Gao, H. Yang, H. Deng, D. Karatkevich, R. Peng, R. A. Schmid, T. Marti

JOURNAL OF THORACIC ONCOLOGY (2021)

暂无数据